Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
Official title: A Smart Phone Application to Improve Adoption of the 2024 KDIGO CKD Guidelines
Run by St. James's Hospital, Ireland · NCT07561957 · Data updated 2026-11-12
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 16 Years to 30 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | St. James's Hospital, Ireland Academic / other |
| Locations | 2 sites (Dublin and 1 other locations) |
| Status | Recruiting |
| Started | January 14, 2026 |
| Main results expected | January 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07561957 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 16–29-year-olds with CKD stages 1–5 who own a smartphone, can provide informed consent, and are engaged with or transitioning through the SJH Young Adult Clinic.
✕Probably not a fit
People aged 30 or older, those without smartphone access, or those with neurocognitive impairment preventing informed consent or app use are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants aged 16–29 with CKD stages 1–5 who own a smartphone will be offered a digital application designed to prompt and support guideline-recommended care and transitional needs. The intervention will be delivered through the St. James's Hospital Young Adult Clinic with coordination from Trinity College Dublin, and use will be tracked alongside clinical data. Outcomes include alignment with KDIGO 2024 recommendations, measures of adherence, and clinical markers such as blood pressure control and proteinuria management. A planned subgroup will specifically examine young people transferring from paediatric to adult services during the co-location of Children's Health Ireland at the St. James's campus.
Why it matters
Potential benefit: If successful, the app could increase adherence to guideline-recommended care, improve blood pressure and proteinuria management, and reduce long-term kidney and cardiovascular risks for young adults with CKD.
How similar studies have gone: Digital interventions in adult kidney disease have shown mixed improvements in guideline adherence and blood pressure control, while transition-focused digital tools for young adults remain relatively understudied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged ≥16 years. * Diagnosed with CKD stages 1-5. * Owns a smartphone and is capable of using mobile applications. * Provides informed consent. Exclusion Criteria: * Inability to provide informed consent due to a neurocognitive impairment. * Age 30 years or older The study will be conducted in the already established SJH Young Adult Clinic, with anticipated expansion coinciding with the co-location Children's Health Ireland (CHI) on site.
Where it's running
-
St. James's Hospital
Dublin, Ireland Recruiting -
Trinity College Dublin
Dublin, Ireland Recruiting
Study contacts
- Principal investigator: Susan McAnallen, MB BCh BAO, MRCPI, ESENeph — St. James's Hospital, Ireland
- Study coordinator: Dr Susan M McAnallen, MB BCh BAO
- Email: sumcanallen@stjames.ie
- Phone: 014103000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nefecon (budesonide) plus ambrisentan for IgA nephropathy with proteinuria
This test will see if combining Nefecon (a gut‑targeted budesonide) with ambrisentan can reduce urine protein and slow kidney decline in adults with IgA nephropathy who have at least 0.5 g of protein in a 24‑hour urine collection.
-
Registry and biobank for resistant nephrotic syndrome treatment responses
This study is collecting information from patients with resistant nephrotic syndrome to see how different treatments work and to help find better options for the future.
-
Long-term safety of Finerenone for children with chronic kidney disease
This study is testing the long-term safety of a medication called Finerenone in children and young adults with chronic kidney disease to see how it works when used with other common treatments.
-
Combining Rituximab and Cyclosporine for Membranous Nephropathy
This study tests if combining two medications, rituximab and cyclosporine, can help people with membranous nephropathy improve their kidney function and reduce protein in their urine.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.